Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Amantadine Hydrochloride, Rebetol®, Tamiflu®
ADS-8902 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ADS-8902 | EXPERIMENTAL | Amantadine and Ribavirin administered with Oseltamivir phosphate |
| Comparator | ACTIVE_COMPARATOR | Oseltamivir Phosphate |
| Name | Type | Description |
|---|---|---|
| Oseltamivir Phosphate | DRUG | Oseltamivir Phosphate, q8h |
| ADS-8902 | DRUG | Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h |
Inclusion Criteria: * Confirmed influenza A by rapid antigen testing * Immunocompromised as defined by recent solid organ or hematopoietic transplant, chronic graft vs. host disease, taking at least 2 immunosuppressants, undergoing chemotherapy, taking high dose chemotherapeutics, HIV positive * Cl...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
ADS-8902 is an investigational small molecule being developed for the treatment of influenza. It is currently in Phase 2 clinical development as a potential antiviral therapy for this infectious disease.
ADS-8902 is being developed by Supernus Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SUPN.
ADS-8902 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for the treatment of influenza.
ADS-8902 has been studied in a Phase 2 clinical trial with the identifier NCT00979251. This completed trial evaluated oral triple combination antiviral drug therapy for influenza A in immunocompromised subjects.
ADS-8902 is a distinct investigational small molecule. It has been studied as part of a triple combination antiviral therapy, but it is not the same as other approved influenza treatments.